22-11-2018
Kieferpix / iStockphoto.com
The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Indivior, generics, Suboxone, Dr Reddy’s, patent infringement, opioid addiction, ANDA, FDA, US Court of Appeals for the Federal Circuit
Fed Circ says Indivior patent was anticipated
30-11-2021
Indivior to launch generic after SCOTUS refuses petition
22-02-2019
Fed Circuit refusal paves way for Suboxone generics
05-02-2019
Indivior obtains court order to block generic Suboxone
18-06-2018
Indivior to appeal court verdict over Suboxone Film patents
04-09-2017
